In the tradition of always seeking the newest and most appropriate treatment for our patients, the physicians of NROC began offering Xofigo as soon as it was approved by the FDA in 2013. Pronounced (Zo-feeg-oh), this Radium 223 injection is used for men whose cancer has spread after receiving medical or surgical therapy that has lowered their testosterone.

Most patients with advanced prostate cancer (approximately 90%) develop bone metastases, and many of them do not have detectable metastases to other organ systems. The bone metastases cause disability including pain, pathological bone adversely.

• Can help extend life by more than 30%
• Goes to the bone, giving off strong energy that kills cancer cells, but does limited damage to nearby healthy cells
• Usually consists of six intravenous injections given at intervals of four weeks

The administration of Xofigo requires the authorized user to have specialized training in the handling of unsealed byproduct materials, and license approval from the
Nuclear Regulatory Commission or Department of Environmental Protection.